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Human herpesviruses (HHVs) are widespread infectious pathogens that have been
associated with proliferative and inﬂammatory diseases. During viral evolution, HHVs have
pirated genes encoding viral G protein-coupled receptors (vGPCRs), which are expressed
on infected host cells. These vGPCRs show highest homology to human chemokine
receptors, which play a key role in the immune system. Importantly, vGPCRs have acquired
unique properties such as constitutive activity and the ability to bind a broad range of human
chemokines. This allows vGPCRs to hijack human proteins and modulate cellular signaling
for the beneﬁt of the virus, ultimately resulting in immune evasion and viral dissemination
to establish a widespread and lifelong infection. Knowledge on the mechanisms by which
herpesviruses reprogram cellular signaling might provide insight in the contribution of
vGPCRs to viral survival and herpesvirus-associated pathologies.
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INTRODUCTION
G PROTEIN-COUPLED RECEPTORS
G protein-coupled receptors (GPCRs) form the largest family of
transmembrane receptors (Pierce et al., 2002). GPCRs are com-
posed of seven transmembrane helices (TMs) surrounding a
central cleft that are connected by three intracellular and three
extracellular loops (ICLs and ECLs, respectively). The amino
terminus (N-terminus) and carboxyl terminus (C-terminus) are
located at the extracellular and intracellular site, respectively
(Katritch et al., 2012; Figure 1). The human genome encodesmore
than 800GPCRs (Fredriksson et al., 2003) and this amount reﬂects
the large diversity of extracellular ligands that they bind. GPCRs
respond to ligands ranging from light, odorants, ions, and cat-
echolamines to neuropeptides and large glycoprotein hormones
(Granier and Kobilka, 2012). GPCRs are involved in nearly all
physiological processes, but also in many pathological conditions
and 30–40% of the current drugs on the market target GPCRs
(Wise et al., 2002). Recent advances in protein engineering and
crystallography aided in the exponential growth of availableGPCR
crystal structures (Tautermann, 2014). These structures provide
insight inGPCR activation andwill aid in drug discovery processes
(Katritch et al., 2013).
The main function of GPCRs is to enable cells to respond to
their environment by converting extracellular stimuli into intra-
cellular responses. Upon binding of a stimulating ligand (i.e.,
agonist), GPCRs undergo conformational changes that lead to
the activation of heterotrimeric GTP binding proteins (G pro-
teins; Oldham and Hamm, 2008). G proteins are composed of
a α, β, and γ subunit. In its inactive state, Gα is bound to
GDP. However, when activated by a GPCR, GDP is exchanged
for GTP (Oldham and Hamm, 2007). As a consequence, the G
protein dissociates from the GPCR and the Gα and Gβγ sub-
units activate effector proteins that produce second messengers,
leading to the activation of transcription factors and eventually
cellular responses (Oldham and Hamm, 2008). Gα proteins can
be subdivided into four families (Figure 2). Gαs proteins stim-
ulate adenylyl cyclase (AC) and the subsequent production of
cyclic AMP (cAMP), whereas Gαi/o proteins inhibit AC. cAMP
in turn activates protein kinase A (PKA), leading to the activation
of cAMP-responsive element (CRE). Gαq/11 proteins stimulate
phospholipase Cβ (PLCβ), an enzyme that catalyzes the forma-
tion of inositol 1,4,5-triphosphate (IP3) and diacylglycerol (DAG)
from phosphatidylinositol-4,5-bisphosphate (PIP2). IP3 in turn
increases intracellular Ca2+ levels by activation of the IP3 receptor
on the endoplasmic reticulum (ER), resulting in the subsequent
activation of protein kinase C (PKC) and nuclear factor of acti-
vated T-cells (NFAT). DAG activates PKC (Rohini et al., 2010).
Gα12/13 proteins activate the small G protein RhoA through the
activation of guanine nucleotide exchange factors (GEFs; McCud-
den et al., 2005). RhoA in turn activates RhoA kinase (ROCK)
and subsequently serum response factor (SRF), which regulates
a variety of cellular responses such as cytoskeletal rearrange-
ment and cell proliferation (Heng and Koh, 2010). In addition
to Gα subunits, the Gβγ subunits themselves are known to
regulate the activity of PLCβ, several AC isoforms and differ-
ent ion channels (McCudden et al., 2005; Milligan and Kostenis,
2006). Furthermore, GPCRs are able to activate signaling in a
G protein-independent manner, for example via β-arrestins (see
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FIGURE 1 |The general architecture of class A G protein-coupled
receptors (GPCRs). Shown are the three extracellular loops (ECL1-3) and
the N-terminus in the EC region and the three intracellular loops (ICL1-3)
and the C-terminus in the IC region. The seven transmembrane (TM)
helices are arranged in a counter-clockwise manner and contain a number
of proline-dependent kinks that divide the GPCR into the ligand binding
module and the module that binds downstream effectors such as G
proteins. The C-terminus of many GPCRs is folded into an eighth helix that
runs parallel to the plasma membrane and is often anchored to the
membrane via a palmitoylation site. Image is based on (Katritch et al., 2012).
“Desensitization and Intracellular Receptor Trafﬁcking of Viral
GPCRs;” Tilley, 2011).
THE CHEMOKINE RECEPTOR SYSTEM
Chemokines bind to chemokine receptors, which form a subfam-
ily of GPCRs. Chemokines are secreted proteins (7–12 kDa) that
play a key role in the immune system as they coordinate themigra-
tion of leukocytes during inﬂammation and immune surveillance
(Rossi and Zlotnik, 2000; Charo and Ransohoff, 2006). So far, 43
chemokines have been identiﬁed in human and they are divided
into four families: C, CC, CXC, and CX3C (Figure 3). Their
classiﬁcation is based on the number and arrangement of con-
served cysteine residues in the N-terminus of chemokines that
form disulﬁde bonds to stabilize tertiary folding. In the CC,
CXC, and CX3C subfamily, none, a single or three amino acids
are inserted between the ﬁrst two of the four conserved cys-
teine residues, respectively (Figure 3). In the C subfamily of
chemokines, the ﬁrst and third cysteine residues are lacking and
only one disulﬁde bond is present (Zlotnik et al., 2006; Blanchet
et al., 2012; Figure 3). Alternatively, chemokines are divided
according to their expression and function. The expression of
inﬂammatory chemokines is induced under inﬂammatory condi-
tions while homeostatic chemokines are constitutively expressed
and are involved in physiological processes such as homeostatic
leukocyte homing (Blanchet et al., 2012). Chemokines bind to gly-
cosaminoglycans (GAGs) on endothelial cells and the extracellular
matrix to immobilize into a chemotactic gradient to directmigrat-
ing cells (Salanga and Handel, 2011; Mortier et al., 2012). The
importance of GAGbinding has been demonstrated by chemokine
mutants that are deﬁcient in GAG binding and unable to recruit
cells in vivo (Hamel et al., 2009). Additionally, CX3CL1 and
CXCL16 are membrane-tethered and facilitate cell–cell adhesion
with cells expressing their respective cognate receptors CX3CR1
and CXCR6, respectively (Ludwig and Weber, 2007).
To date, 23 chemokine receptors have been identiﬁed, which
are classiﬁed according to the speciﬁc subclass of chemokines that
they bind. Only one XC and one CX3C receptor exist, whereas
ten CC and six CXC receptors have been identiﬁed as of yet. The
chemokine/chemokine receptor system is rather complex as many
receptors can bind multiple chemokines and vice versa (Figure 4).
Activated chemokine receptors mainly signal through Gαi/o pro-
teins tomediate chemotaxis (Neptune andBourne, 1997). ViaGβγ
subunits, chemokine receptors activate PI3Kγ and PLCβ, the latter
resulting in an increased Ca2+ ﬂux (Thelen, 2001). Furthermore,
chemokine receptors activate mitogen-activated protein (MAP)
kinases such as extracellular-signal-regulated kinases ERK1/2, p38
and c-Jun N-terminal kinases (JNK) but also Rho GTPases (e.g.,
RhoA and Rac) via Gα12/13 that mediate the reorganization of the
actin cytoskeleton (Thelen, 2001; Thelen and Stein, 2008; Cot-
ton and Claing, 2009). Besides the classical chemokine receptors,
ﬁve atypical chemokine receptors (ACKR) have been identiﬁed,
named ACKR1 (DARC), ACKR2 (D6), ACKR3 (CXCR7), ACKR4
(CCX-CKR), and ACKR5 (CCRL2; Figure 4). These receptors
do not induce migration upon chemokine binding or activate
G protein-dependent signaling, but recruit β-arrestin (Galliera
et al., 2004; Rajagopal et al., 2010; Ulvmar et al., 2011; Canals
et al., 2012; Watts et al., 2013). The ACKRs are believed to acts
as decoy receptors that scavenge chemokines from the extracellu-
lar environment to limit the recruitment of leukocytes (Bonecchi
et al., 2010). However, it was recently proposed that Gi/o proteins
impair ACKR4-mediated signaling. Preventing the interaction
with Gi/o proteins by treating cells with pertussis toxin (PTX)
unmasked signaling of ACKR4 to CRE (Watts et al., 2013). Fur-
thermore, ACKR2 activates a β-arrestin1-dependent signaling
cascade, resulting in the phosphorylation of coﬁlin (Borroni et al.,
2013).
Besides their role in the immune system, chemokine recep-
tors are also involved in other physiological processes including
development, tissue repair, angiogenesis, and neuroprotection
(Strohmann et al., 1974; Kiefer and Siekmann, 2011; Jaerve
and Muller, 2012; Martins-Green et al., 2013). Dysregulation of
chemokines and their receptors may result in an excessive inﬁl-
tration of leukocytes into tissue. Indeed, chemokine receptors
are involved in several inﬂammatory diseases such as arthri-
tis, multiple sclerosis, asthma, psoriasis, Crohn’s disease and
atherosclerosis (Bendall, 2005; Cardona et al., 2013; Marra and
Tacke, 2014). Moreover, chemokine receptors also play a role in
oncogenesis by inducing proliferation and metastasis (Koizumi
et al., 2007; Wu et al., 2009; Lazennec and Richmond, 2010).
Furthermore, CXCR4 and CCR5 act as co-receptors to medi-
ate HIV entry into macrophages and T-cells (Berger et al., 1999).
CCR5 (Xu et al., 2014) and CXCR4 (De Clercq, 2010) antagonists
are on the market for the treatment of CCR5-tropic HIV infec-
tion and to promote mobilization of hematopoietic stem cells in
transplant patients, respectively. Furthermore, the CCR4 mon-
oclonal antibody Mogamulizumab has been approved in Japan
for the treatment of adult T-cell leukemia-lymphoma (Yoshie and
Matsushima, 2014).
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FIGURE 2 | G protein-dependent signaling. Gα proteins are divided
into Gαs, Gαi , Gαq, and Gα12/13 protein families that regulate different
effector proteins such as AC and PLC. Effector proteins produce second
messengers (e.g., cAMP) that subsequently activate transcription factors
such as CRE, NFAT and SRF. AC, adenylyl cyclase; ATP, adenosine
triphosphate; cAMP, cyclic adenosine monophosphate; CRE,
cAMP-responsive element; DAG, diacylglycerol; GEF, guanine nucleotide
exchange factor; IP3, inositol 1,4,5-triphosphate; NFAT, nuclear factor of
activated T-cells; PIP2, phosphatidylinositol-4,5-bisphosphate; PKA, protein
kinase A; PKC, protein kinase C; PLCβ, phospholipase Cβ; RhoA, Ras
homolog gene family A; ROCK, RhoA kinase; SRF, serum response
factor.
FIGURE 3 | Chemokine subclasses. Chemokines are divided into four
families according to the number and spatial organization of conserved
cysteine residues in their N-terminus. Disulﬁde bridges are shown as black
lines. The transmembrane domain of CX3CL1 is depicted by lipids (in gray).
HERPESVIRUSES-ENCODED GPCRs
Human herpesviruses (HHVs) are double-stranded DNA viruses
that establish a lifelong latent infection in the host (Vischer
et al., 2006a,b). During latent infection, viral gene expression
is highly suppressed and limited to a few genes that main-
tain the latent state and serve to evade immune detection. In
the lytic phase, the majority of viral genes are expressed and
viral DNA is replicated, leading to the production and release
of infectious virions and the subsequent lysis of the host cell.
Latent infections are usually asymptomatic. However, reactivation
of the virus in immunocompromised patients (e.g., transplant
recipients or AIDS patients) could lead to the development of
serious pathologies (Cesarman, 2014b; Vischer et al., 2014). The
HHVs are divided into α, β, and γ subfamilies based on their
biological properties and sequence similarity (McGeoch et al.,
2000). Members of the α subfamily are the human simplex
virus (HSV)1 (HHV1), HSV2 (HHV2), and varicella zoster
virus (HHV3). The subfamily of β herpesviruses consists of the
human cytomegalovirus (HCMV; HHV5) and the Roseoloviruses
(HHV6 and HHV7). Kaposi’s sarcoma-associated herpesvirus
(KSHV; HHV8) and Epstein-Barr virus (EBV; HHV4) form the
γ herpesvirus subfamily.
The β and γ herpesviruses encode homologs of human
chemokine receptors andmost of these receptors bind chemokines
(Figure 4). These viral GPCRs (vGPCRs) have probably been
derived from the host genome during evolution and modiﬁed to
successfully redirect the functions of the host cells in favor of the
virus. Some of these vGPCRs are involved in (proliferative) dis-
eases (Figure 5; Vischer et al., 2006a,b, 2014; Slinger et al., 2011).
The α herpesviruses do not encode GPCRs and are outside the
scope of this review.
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FIGURE 4 | Chemokines and their human and viral receptors.The
chemokines (vertical) are divided into four families (colors match with
Figure 3) and the virus-encoded chemokines are also included at the bottom
in black. Human chemokine receptors (horizontal) are classiﬁed according to
the chemokines they bind and the a-typical chemokine receptors-5 (ACKR1-5)
are also included. Viral receptors are depicted on the right. A colored dot
represents the pairing of a chemokine to a speciﬁc receptor. One receptor
can bind multiple chemokines and vice versa. No receptor has hitherto been
identiﬁed for CXCL14 and the vGPCRs BILF1, US27, UL33, and UL78 are
classiﬁed as orphan receptors as no chemokines have been identiﬁed to bind
these receptors. The distribution of the colored dots shows that human
chemokine receptors only bind chemokines within their own class. However,
ACKR1 and some vGPCRs cross this boundary as they bind CC, CXC, and
CX3CL1 chemokines. Moreover, KSHV-encoded vCCL2 binds promiscuously
to XC, CC, CXC, and CX3C chemokine receptors. The diagram is based on
(Bachelerie et al., 2014; Steen et al., 2014).
Kaposi’s sarcoma-associated herpesvirus
The KSHV genome is approximately 160 kbp long and encodes
over 80 open-reading frames (Arvanitakis et al., 1996; Russo et al.,
1996). KSHV is mainly spread via saliva, but could also be trans-
mitted via contaminated blood and tissues transplants (Minhas
and Wood, 2014) and infects endothelial cells via the interaction
with integrins, heparin sulfates, and the ephrin receptor tyrosine
kinase (RTK) A2 (Blackbourn et al., 2000; Akula et al., 2002;
Kaleeba andBerger,2006;Hahnet al.,2012; Garrigues et al., 2014).
Moreover, B cells, monocytes/macrophages and dendritic cells
are also permissive to KSHV infection (Blackbourn et al., 2000;
Rappocciolo et al., 2006;Hassman et al., 2011; Dollery et al., 2014).
The seroprevalence of KSHV depends on the geographical areas
with infection rates up to 50% in Africa but only a few percent in
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FIGURE 5 | Human herpesviruses (HHVs)-encoded GPCRs. HHVs
are divided into three subfamilies: the γ-herpesviruses (left), the
β-herpesviruses (right), and the α-herpesviruses (not shown) and have
been associated with several human diseases, including proliferative
diseases. HHVs from the β and γ subfamilies encode one or more
vGPCRs that show closest sequence identity to cellular chemokine
receptors (percentage amino acid identity is shown between brackets).
These vGPCRs have most likely been pirated from the human genome
during viral evolution and function to modify cellular signaling. CKR,
chemokine receptor; CNS, central nervous system; KS, Kaposi’s
sarcoma; MCD, multicentric Castleman’s disease; PEL, Primary effusion
lymphoma.
the rest of theworld (Hayward,1999; Dedicoat andNewton,2003).
Latent infection of KSHV is often asymptotic. However, reactiva-
tion in immunosuppressed individuals can cause the development
of proliferative disorders (Figure 5; Martin, 2007; Vischer et al.,
2014). KSHV was ﬁrst detected in 1994 in the Kaposi’s sarcoma
(KS) lesions of an AIDS patient (Chang et al., 1994). KS is a
highly vascularized neoplasm often found as red patches on the
skin, but can also be presented in the oral cavity, lymph nodes
and viscera. The tumor is composed of KSHV-infected spindle-
shaped tumor cells of vascular and lymphatic endothelial origin,
inﬁltrating inﬂammatory cells and red blood cells. Four different
variants of KS are recognized. Classic KS affects middle-aged men
of Mediterranean descent and is often benign. African endemic
KS can be more aggressive and may also affect young children.
AIDS-associated KS is the most aggressive form of KS and typi-
cally involves disseminated lesions that affect organs. IatrogenicKS
is associated with drugs-induced immunosuppression after trans-
plantation (Radu and Pantanowitz, 2013). KSHV has also been
associated with two rare lymphoproliferative disorders. Primary
effusion lymphoma (PEL) is a HIV-associated non-Hodgkin’s
lymphoma that arises in body cavities such as the pleural space,
pericardium, andperitoneum. Dissemination of these lymphomas
is not uncommon and the prognosis for patients with PEL is
poor (Chen et al., 2007). Multicentric Castleman’s disease (MCD)
involves the hyperproliferation of B cells in lymph nodes that
may progress into lymphoma (Dittmer et al., 2012; Cesarman,
2014a).
KSHV encodes a single GPCR named ORF74, which shows
highest sequence identity to human CXCR2 (Figure 5; Vischer
et al., 2006b). Expression of ORF74 is detected in KS lesions
(Cesarman et al., 1996; Staskus et al., 1997). Moreover, transgenic
expression of ORF74 in mice is sufﬁcient for the development of
vascular KS-like lesions (Yang et al., 2000; Guo et al., 2003), indi-
cating that ORF74 is a key player in the initiation of KS. ORF74 is a
lytic gene which expression is regulated by the KSHV lytic master-
switch proteinORF50 (Liang andGanem,2004). However, the role
of a lytic gene in oncogenesis seems contradictory as cells express-
ing these genes eventually die when new virions are released. It has
been proposed that immunosuppression or co-infection withHIV
results in the dysregulated expression of ORF74 in non-lytic cells
(Jham and Montaner, 2010). Furthermore, ORF74 is expressed in
only a subset of KS tumor cells, but is able to transform neighbor-
ing cells by inducing the secretion of paracrine factors (Pati et al.,
2001; Montaner et al., 2004; Martin and Gutkind, 2009). Indeed,
selectively targeting ORF74-expressing cells in established tumors
also resulted in apoptosis of adjacent cells that do not express
ORF74 (Montaner et al., 2006).
Epstein-Barr virus
The genome of EBV has a size of 184 kbp and encodes approxi-
mately 84 open reading frames (Baer et al., 1984). EBV is primarily
spread via saliva and widely distributed with 90% of the popula-
tion being infected by their twenties (White et al., 2014). EBV
infects B lymphocytes and epithelial cells via integrins and HLA
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class II molecules (Li et al., 1997; Haan et al., 2000; Dorner et al.,
2010; Hutt-Fletcher and Chesnokova, 2010). EBV was one of
the ﬁrst discovered tumor viruses and was initially observed
in cells derived from Burkitt’s lymphoma (Epstein et al., 1964).
Later it was discovered that EBV is also involved in other cancer
types such as Hodgkin’s lymphoma and nasopharyngeal carci-
noma (Figure 5; Thompson and Kurzrock, 2004; Carbone et al.,
2008).
EBV expresses a single GPCR named BILF1, which is expressed
as an early lytic gene (Beisser et al., 2005). BILF1 shows highest
sequence similarity to CXCR4 (Figure 5) and plays a role in escap-
ing immune recognition by downregulating the surface expression
of MHC class I proteins (Zuo et al., 2011; Grifﬁn et al., 2013).
MHC class I proteins present peptides derived from foreign pro-
teins to cytotoxic T cells (Hewitt, 2003). As such, BILF1 reduces
the activation of CD8+ T cells (Zuo et al., 2009). Furthermore,
BILF1 inhibits the phosphorylated RNA-dependent protein kinase
R (PKR),which plays a role in antiviral immune responses (Beisser
et al., 2005).
Human cytomegalovirus
HCMV has the largest genome of the HHVs of approximately
230 kbp that is divided into a unique large (UL) and unique
short (US) region. HCMV encodes over 200 open reading frames,
but the exact number is depending on the strain (Murphy et al.,
2003a,b; Stern-Ginossar et al., 2012). HCMV infects endothelial,
epithelial, ﬁbroblasts, and smooth muscle cells (Sinzger et al.,
2008) via integrins (Feire et al., 2004, 2010) and growth fac-
tor receptors (Wang et al., 2003; Soroceanu et al., 2008) and is
disseminated via latently infected monocytes. Differentiation of
monocytes into macrophages leads to reactivation of HCMV and
production of infectious virions (Streblow and Nelson, 2003).
HCMV is found in the liver, gastrointestinal track, lungs, retina,
and brain and widely spread among the population with a sero-
prevalence ranging from 50–100% (Gandhi and Khanna, 2004;
Bate et al., 2010; Cannon et al., 2010). Primary infection or reacti-
vation of HCMV in immunocompromised hosts can cause severe
and fetal conditions such as damage to HCMV-positive organs
(the liver, lungs, brain, and retina; Figure 5; Landolfo et al., 2003).
Furthermore, HCMV is associated with vascular diseases such as
atherosclerosis, inﬂammatory, and autoimmune diseases (Gom-
bos et al., 2013). HCMV infection during pregnancy might cause
severe problems to the unborn child, such as neurosensory hearing
loss or mental retardation (Carlson et al., 2010). Primary HCMV
infection in transplantation patients may cause graft rejection and
diseases to the donor organ (Cainelli and Vento, 2002; Ishibashi
et al., 2011). Finally, HCMV infection is associated with vari-
ous malignancies including colon cancer (Mariguela et al., 2008;
Bongers et al., 2010) and glioblastoma (Cobbs, 2013). HCMV
has been proposed to act as an oncomodulator rather than an
oncogenic virus. HCMVpreferentially infects cancer cells and reg-
ulates the expression of oncogenic and tumor suppressor genes
(Michaelis et al., 2009; Soderberg-Naucler and Johnsen, 2012).
HCMV encodes four GPCRs: US27, US28, UL33, and UL78.
These vGPCRs display highest sequence identity to human
chemokine receptors CXCR3, CX3CR1, CCR10, and CXCR1,
respectively (Figure 5; Vischer et al., 2006b). US28 (Zipeto et al.,
1999) and UL78 (Michel et al., 2005) are expressed early after
HCMV infection whereas US27 (Margulies and Gibson, 2007)
and UL33 (Bodaghi et al., 1998) are expressed with late kinetics.
In addition, the protein products of the HCMV-encoded GPCRs
are found in viral particles (Bodaghi et al., 1998), which indi-
cates that these vGPCRs might contribute to viral dissemination.
UL78 (O’Connor and Shenk, 2012) and US27 (O’Connor and
Shenk, 2011) have been proposed to play a role in the viral life
cycle and dissemination. A speciﬁc role for US28 in the onco-
modulatory properties of HCMV has been postulated due to the
proliferative, pro-angiogenic, and pro-inﬂammatory signaling of
US28 (Maussang et al., 2006). Moreover, US28 was detected in
glioblastoma specimens from patients (Slinger et al., 2010; Soro-
ceanu et al., 2011). Furthermore, US28 induces the migration of
inﬂammation-associated cells that are often involved in vascular
diseases, such as vascular smooth muscle cells and macrophages
(Vomaske et al., 2009). In addition, US28 acts as a co-receptor for
HIV entry (Pleskoff et al., 1997).
Roseoloviruses
Roseoloviruses consist of three highly related species: HHV6A,
HHV6B, and HHV7. These species have a similar genomic
organization, but differ in their epidemiologic and biological char-
acteristics. The sequence identity between HHV6A and 6B is 90%
and the genome size of both variants is approximately 160 kbp
(Dominguez et al., 1999). HHV6A and 6B encode 110 and 119
open reading frames, respectively (Caselli and Di Luca, 2007).
The genome of HHV7 has a size of approximately 150 kbp and
encodes 84 open reading frames (Caselli and Di Luca, 2007).
HHV6 is probably transmitted via saliva (Tang and Mori, 2010)
and enters cells via the interaction with CD46 (Tang and Mori,
2010). HHV6 establishes latency mainly in monocytes, but also in
bone marrow progenitors, the salivary glands, and the central ner-
vous system, but replicates most efﬁciently in CD4+ T cells (De
Bolle et al., 2005). HHV7 persists latently in T lymphocytes and
uses CD4 for cell entry (Lusso et al., 1994). Infection with Rose-
oloviruses often occurs during early childhood and seroprevalence
in adults is almost 100% (Emery and Clark, 2007). Primary infec-
tion with HHV6 (and less common with HHV7) in children can
lead to Roseola infantum, an illness characterized by fever and rash
(Figure 5; Tanaka et al., 1994; Tang et al., 2010). Furthermore,
reactivation of Roseoloviruses in immunocompromised hosts is
associated with diseases of the central nervous system such as
encephalitis, encephalopathy, and multiple sclerosis, but also with
pneumonitis, hepatitis, bone marrow suppression, and rejection
of transplanted organs and even death (Campadelli-Fiume et al.,
1999; Schwartz et al., 2014).
Both HHV6 and HHV7 encode two GPCRs: U12 and U51.
HHV6-U12 shares highest sequence similarity with CCR10,
HHV7-U12 with CX3CR1, HHV6-U51 with CCR7 and HHV7-
U51 with CCR2 (Figure 5; Vischer et al., 2006b). U51 is expressed
early after viral infection (Menotti et al., 1999), whereas U12 is a
late gene expressed during lytic infection (Isegawa et al., 1998).
vGPCRs MODULATE CELLULAR SIGNALING
To persist in the host and to replicate and spread themselves is
of vital importance for viruses. To achieve this, viruses such as
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the herpesviruses developed multiple strategies. For example, a
large amount of viral gene products of herpesviruses is dedi-
cated to evade antiviral immune responses (Grifﬁn et al., 2010).
Most of the vGPCRs show highest sequence identity to human
chemokine receptors. Considering the functions of chemokine
receptors, herpesviruses might use vGPCRs for immune evasion
and/or viral replication and dissemination by inducing prolifer-
ation and chemotaxis of infected cells. vGPCRs have developed
multiple ways to modulate cellular signaling for the beneﬁt of the
virus. Hijacking of human chemokines andG proteins by vGPCRs
have been the subject of many studies. However, exploiting human
cellular trafﬁcking proteins or modulating the function of human
receptors from the GPCR or receptor tyrosine kinase (RTK) class
might be alternative strategies of the virus to modulate cellular
responses in favor of the virus.
vGPCRs HIJACK CHEMOKINES
In contrast to their human counterparts, most vGPCRs are con-
stitutively active (see also “vGPCRs Hijack Human G Proteins”
and “Molecular Determinants of the Constitutive Activity of Viral
GPCRs”), meaning that they can activate signaling pathways in
a ligand-independent manner. However, most vGPCRs are also
able to bind human and viral chemokines that modulate this con-
stitutive activity in some cases or to activate ligand-dependent
signaling. In contrast to human chemokine receptors, vGPCRs
can bind chemokines from several families (Figure 4).
Chemokine binding to KSHV-encoded ORF74
ORF74 binds a broad range of CXC chemokines that also bind
to its closest human homolog CXCR2: CXCL1-3 and CXCL5-8
(Rosenkilde et al., 1999). ORF74 binds also to CXCL4, CXCL10
(CXCR3 agonist), and CXCL12 (CXCR4 agonist), which do
not bind to CXCR2 (Gershengorn et al., 1998; Rosenkilde et al.,
1999). Furthermore, ORF74 binds to CCL1 and CCL5 (Figure 4;
Arvanitakis et al., 1997). These human chemokines modulate the
constitutive activity of ORF74 toward different signaling pathways
that are described in Section “G Protein-Dependent ORF74 Sig-
naling”. CXCL1 and CXCL3 are full agonists, whereas CXCL2 acts
as a partial agonist. CXCL4,CXCL5,CXCL7, andCXCL8 behave as
low-potency agonists. CXCL10 and CXCL12 are full inverse ago-
nists and CXCL6 is a partial inverse agonist (Geras-Raaka et al.,
1998b,c; Gershengorn et al., 1998; Rosenkilde et al., 1999). Fur-
thermore, KSHV encodes three viral chemokines: vCCL1, vCCL2,
and vCCL3 (Figure 4). vCCL2 acts as a partial inverse agonist for
ORF74 (Geras-Raaka et al., 1998b), as an antagonist for several
human chemokine receptors expressed on T helper 1 (TH1) cells
and as an agonist for CCR3 and CCR8 expressed on TH2 cells
(Nicholas, 2010). vCCL1 and vCCL3 are agonists of human CCR8
and CCR4, respectively, and thereby attract TH2 cells, which are
less effective against pathogens as compared to TH1 cells (Coscoy,
2007).
Similar to human chemokine receptors (Scholten et al., 2012),
the N-terminus of ORF74 is essential for high afﬁnity chemokine
binding (Ho et al., 1999). The N-terminus contains two tyro-
sine (Y) residues, which are post-translationally modiﬁed by
sulfate groups. Aspartic acid-substitution of these Y residues
diminished sulfation of ORF74 but did not affect constitutive
signaling of ORF74. However, CXCL1 binding to this mutant
was impaired, whereas CXCL10 binding was preserved compared
to wild type (WT)-ORF74 (Feng et al., 2010). This suggests that
CXCL1 and CXCL10 differentially interact with the N-terminus of
ORF74. Interestingly, the ORF74 mutant lacking sulfo-tyrosines
did not form tumors in a xenograft mouse model, as com-
pared to WT-ORF74, suggesting that CXCL1-induced signaling
of ORF74 is essential for tumor formation in mice (Feng et al.,
2010). Similar conclusionswere drawn from the transgenic expres-
sion of an N-terminal deletion mutant, that is constitutively
active but unable to bind chemokines, and did not develop
KS-like lesions in mice (Holst et al., 2001). Furthermore, the
double mutant ORF74-R5.35(208)H/R5.39(212)H is constitutively
active and responsive to inverse agonists, but not to agonists.
When this mutant is expressed in transgenic mice, a smaller
fraction of mice develop KS-like disease and with a reduced
severity compared to mice expressing WT-ORF74 (Holst et al.,
2001).
Chemokine binding to EBV-encoded BILF1
No ligands have hitherto been identiﬁed for BILF1 (Figure 4).
Therefore, BILF1 has been classiﬁed as an orphan receptor.
Chemokine binding to HCMV-encoded GPCRs
US28 binds CX3CL1, several chemokines from the CC family
(e.g., CCL2 and CCL5; Gao and Murphy, 1994; Kuhn et al., 1995;
Kledal et al., 1998) and KSHV-encoded vCCL2 (Figure 4; Kledal
et al., 1997). Human CCL5 and CX3CL1 differentially interact
with the US28 N-terminus (Casarosa et al., 2005) and differen-
tially modulate (constitutive) US28 signaling, as further discussed
in Section “G Protein-Dependent Signaling of HCMV-Encoded
GPCRs” (Vomaske et al., 2009).
The medium of HCMV-infected ﬁbroblasts contains lower
levels of CCL2 and CCL5 as compared to the medium of
uninfected ﬁbroblasts, which is not due to decreased transcrip-
tional activity (Michelson et al., 1997; Bodaghi et al., 1998) or
degradation by soluble proteases (Michelson et al., 1997), but
is instead the result of the co-internalization of chemokines
with US28 (Michelson et al., 1997; Bodaghi et al., 1998; Bill-
strom et al., 1999). This chemokine scavenging might be an
immune evasion strategy to regulate chemokine levels avail-
able for human chemokine receptors and subsequently limit
attraction of surrounding immune cells at sites of infection.
Indeed, the supernatant fromHCMV-infectedﬁbroblasts is unable
to induce migration of monocytes (Randolph-Habecker et al.,
2002). On the other hand, monocyte adhesion to a mono-
layer of endothelial cells that express US28 through retroviral
transduction is not inhibited as compared to cells transduced
with empty virus, indicating that chemokine scavenging by
US28 is insufﬁcient to affect monocyte adhesion (Boomker et al.,
2006).
Furthermore, binding of US28 tomembrane-tethered CX3CL1
of the host cell promotes cell-to-cell contact and might conse-
quently facilitate viral dissemination (Kledal et al., 1998). Indeed,
an US28-deletion mutant of HCMV (HCMV-US28) shows a
signiﬁcant decrease in cell-to-cell infection of epithelial cells, as
compared to WT-HCMV (Noriega et al., 2014).
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The other three HCMV-encoded GPCRs US27, UL33, and
UL78 are classiﬁed as orphan receptors as they do not seem to
interact with chemokines or other ligand types as of yet.
Besides viral GPCRs, HCMV also encodes two viral
chemokines. vCXCL1 induces Ca2+ mobilization in L1.2 cells sta-
bly transfected with CXCR1 or CXCR2 (Figure 4), whereas no
Ca2+ response was observed in cells expressing any of the other
human chemokine receptors tested (Luttichau, 2010). No recep-
tor for vCXCL2 has hitherto been identiﬁed and it remains to be
investigated whether these HCMV-encoded chemokines are able
to bind viral GPCRs.
Chemokine binding to Roseoloviruses-encoded GPCRs
U12 and U51 encoded by HHV6 and HHV7 bind to different
chemokines. HHV6-U12 binds to CCL2-5, while HHV7-U12
binds to CCL17, CCL19, CCL21, and CCL22. Likewise, HHV6-
U51 binds to several CC-chemokines, CX3CL1, XCL1 (Catusse
et al., 2008), and KSHV-encoded vCCL2 (Milne et al., 2000),
whereas HHV7-U51 only binds CC-chemokines (Figure 4). Sig-
naling mediated by HHV6-U12 (Isegawa et al., 1998) and HHV7-
U12 (Tadagaki et al., 2005) is dependent on chemokines and the
constitutive activity of HHV6-U51 is differentially regulated by
chemokines, as further discussed in Section“GProtein-Dependent
Signaling of Roseoloviruses-Encoded GPCRs”. Besides chemokine
binding, U51 may subvert recognition by the immune system
by decreasing CCL5 concentrations at the transcriptional level
in stably transfected epithelial and erythroleukemia cells and in
HHV6-infected T lymphocytes (Milne et al., 2000; Catusse et al.,
2008).
HHV6 encodes the chemokine vCCL4, which binds to
human CCR2 and activates Ca2+ mobilization and migration
of CCR2-expressing L1.2 cells (Luttichau et al., 2003). Hence,
HHV6 might utilize vCCL4 to attract CCR2-expressing cells (i.e.,
monocytes/macrophages) for infection and to establish latency
(Luttichau et al., 2003).
vGPCRs HIJACK HUMAN G PROTEINS
Most agonist-occupied GPCRs activate downstream signaling via
the coupling and activation of heterotrimericGproteins. The crys-
tal structure of the activeβ2 adrenergic receptor (β2AR) in complex
with Gαs revealed that R3.50(131; Ballesteros–Weinstein residue
numbering (Ballesteros andWeinstein, 1995) followed by UniProt
residue numbering) of β2AR packs against Gαs (Rasmussen et al.,
2011), suggesting a direct interaction. R3.50 is part of the DRY
(aspartic acid–arginine–tyrosine) motif, which is located at the
boundary of TM3 and ICL2 and plays a key role in G protein
activation. The DRY motif is one of the most conserved motifs
among rhodopsin-like GPCRs with R3.50 being the most con-
served (96%; Mirzadegan et al., 2003). Mutation of R3.50 impairs
G protein signaling of many GPCRs (Rovati et al., 2007).
G protein-dependent ORF74 signaling
In contrast to its human homolog CXCR2, ORF74 couples con-
stitutively and promiscuously to Gαi, Gα12/13, and presumably
Gαq [the latter was suggested from the PTX-insensitive acti-
vation of PLC in transiently transfected COS-7 cells (Shepard
et al., 2001; Smit et al., 2002; Cannon and Cesarman, 2004;
Rosenkilde et al., 2004; Verzijl et al., 2004)]. G protein cou-
pling leads to the constitutive activation of a variety of signal
transduction cascades that contribute to the oncogenic prop-
erties of ORF74. For example, ORF74 constitutively activates
MAP kinases such as ERK1/2, p38, and JNK in both a PTX-
sensitive and -insensitive manner (Bais et al., 1998; Munshi et al.,
1999; Sodhi et al., 2000; Smit et al., 2002), which may promote
the expression of growth-promoting genes. Interestingly, ERK
is activated in ORF74-expressing COS-7 cells (Smit et al., 2002)
but not in HEK293T cells (Bais et al., 1998), showing cell-type-
dependency of ORF74 signaling. Furthermore, the activation of
PI3K andAkt protects cells from apoptosis (Montaner et al., 2001)
and may therefore contribute to the survival of KSHV-infected
cells. Constitutive Akt activation by ORF74 leads to activation
of the TSC2/mTOR pathway in transiently transfected COS-7
cells (Sodhi et al., 2006). Inhibition of mTOR activity leads to
tumor regression in a KS mouse model, whereas mTOR overex-
pression was sufﬁcient to render endothelial cell oncogenic when
injected in mice (Sodhi et al., 2006). Additionally, ORF74 consti-
tutively activates members of the Rho family of small guanosine
triphosphatases (GTPases) such as RhoA (Shepard et al., 2001;
Martin et al., 2007) and Rac1 (Montaner et al., 2004) in trans-
fected HEK293T, NIH-3T3, and porcine aortic endothelial cells
via Gα12/13 proteins. Rac1 is overexpressed in spindle cells from
KS biopsies and expression of a constitutively active Rac1 (Ma
et al., 2009) or RhoA (Martin et al., 2007) in transgenic mice
causes the development of KS-like tumors, whereas inhibition
of Rac1 (Montaner et al., 2004) or knockdown of RhoA expres-
sion (Martin et al., 2007) reduces ORF74 tumorogenesis in vivo.
Most of these constitutively activated signaling pathways (i.e., PLC,
ERK, Akt, and NFAT activation) are modulated by chemokines
as described in Section “Chemokine Binding to KSHV-Encoded
ORF74” (Rosenkilde et al., 1999; Smit et al., 2002).
These pathways lead to the constitutive activation of numer-
ous transcription factors including nuclear factor κ-light-chain-
enhancer of activated B cells (NF-κB), NFAT, CRE, activator
protein 1 (AP1) and hypoxia-inducible factor 1α (HIF-1α) in
different cell lines [e.g., COS-7, HEK293, T cells, and mono-
cytes, but also more relevant cells such as KSHV-positive primary
B cells derived from KS patients (Azzi et al., 2013), the KS-
derived endothelial cell line KSIMM, primary endothelial cells
(Pati et al., 2001), and PEL cells (Cannon and Cesarman, 2004)].
Constitutive NF-κB activation is partly inhibited by PTX, show-
ing a contribution of Gαi/o coupling (Cannon and Cesarman,
2004; Verzijl et al., 2004). However, the agonistic effects of the
murine chemokines CXCL1 and CXCL2 were insensitive to PTX,
suggesting that agonists induce a switch in G protein coupling
(Verzijl et al., 2004). HIF-1α regulates the expression of vascular
endothelial growth factor (VEGF),which contributes to the angio-
genic potential of ORF74 (Sodhi et al., 2000). AP-1, NFAT, and
NF-κB are important mediators of the expression of cytokines
such as CXCL1, CXCL8, and IL-6 in HEK293T cells, mono-
cytes (Schwarz and Murphy, 2001), endothelial cells and KSIMM
cells (Pati et al., 2001), which produce an inﬂammatory environ-
ment that promotes transformation of cells and contributes to
KS (Cesarman et al., 2000). These secreted factors promote pro-
liferative and pro-angiogenic signaling in an autocrine, but also
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paracrine manner by activating neighboring cells that do not
express ORF74 (Sodhi et al., 2004a). In addition, these secreted
paracrine factors might attract host cells that are potentially
infected by new KSHV viruses and thereby contribute to viral
dissemination.
TheDRYmotif is less conserved among vGPCRs andmost vari-
ety is observed within D3.49 (Jensen et al., 2012). Indeed, ORF74
contains a VRY motif and mutation of the DRY motif of CXCR2
into VRY introduces constitutive activity to this human homolog
of ORF74 constitutively active (Burger et al., 1999). Reciprocally,
introducing a DRY motif in ORF74 did not have major effects
on its signaling properties (Rosenkilde et al., 2000). On the other
hand, substitution of R3.50(143) with alanine results in a non-
functional mutant of ORF74 (Ho et al., 2001) that lacks oncogenic
potential (Sodhi et al., 2004b; Chaisuparat et al., 2008). Hence,
G protein-dependent signaling is essential for ORF74 Kaposi’s
sarcomagenesis. Interestingly, the equine herpesvirus 2 (EHV2)-
encoded ORF74 lacks the conserved R3.50 but is functionally and
constitutively coupled to Gαi in HEK293T cells (Rosenkilde et al.,
2005).
G protein-dependent BILF1 signaling
BILF1 constitutively activates the transcription factor NF-κB and
inhibits CRE via Gi proteins in transfected COS-7 cells (Beisser
et al., 2005; Paulsen et al., 2005). In contrast, BILF1 is unable
to constitutively modulate NF-κB-mediated gene activation but
activates CRE-mediated transcription in Burkitt’s lymphoma and
lymphoblastoid B cells (Beisser et al., 2005), showing that BILF1
signaling can be cell type dependent. BILF1 exhibits the sequence
EKT instead of the DRY motif. BILF1-k3.50(122)A is unable to
inhibit the forskolin-induced increase in cAMP (Lyngaa et al.,
2010), but still induces tumor growth in a xenograft mouse model
(Lyngaa et al., 2010). This suggests that G protein-independent
signaling contributes to tumor development. Introduction of a
DRY motif yielded a less active mutant of BILF1 compared to
WT-BILF1 with respect to cAMP signaling (Lyngaa et al., 2010).
G protein-dependent signaling of HCMV-encoded GPCRs
US28 constitutively activates proliferative, pro-survival, and pro-
inﬂammatory signaling pathways. For example, US28 consti-
tutively activates PLC in transfected COS-7 or NIH-3T3 cells
(Casarosa et al., 2001;Waldhoer et al., 2002; Maussang et al., 2006)
and HCMV-infected smooth muscle cells and U373 glioblastoma
cells (Miller et al., 2012). Constitutive signaling via Gαq and Gαi
proteins eventually leads to the activation of transcription factors
such as NFAT, NF-κB, CRE, and SRF (McLean et al., 2004), result-
ing in the upregulation of cyclinD1 (Maussang et al., 2006),VEGF
(Maussang et al., 2006), COX-2 (Maussang et al., 2009a),β-catenin
(Langemeijer et al., 2012), and IL-6 (Slinger et al., 2010) in COS-
7, HEK293T, NIH-3T3 cells, and HCMV-infected glioblastoma
cells. Secreted IL-6 activates the proliferative IL-6/JAK1/STAT3
signaling axis (Slinger et al., 2010).
US28 also signals in a ligand-dependent manner. CCL5 is
required for the US28-mediated activation of RhoA (Melnychuk
et al., 2004), focal adhesion kinase (FAK), and ERK (Vomaske
et al., 2009) via Gα12/13 proteins in smooth muscle cells, mouse
ﬁbroblasts andU373 glioblastoma cells infectedwith adenoviruses
expressing US28, whereas CX3CL1 activates FAK and ERK via
Gαq in ﬁbroblasts. US28 adenovirus-expressing smooth muscle
cells migrate toward CCL5, whereas CX3CL1 antagonizes this
effect (Vomaske et al., 2009). On the other hand, CX3CL1 (but
not CCL5) induces migration of US28-expressing macrophages
(Vomaske et al., 2009), showing that the effect of chemokines
can be cell type dependent. The migration of HCMV-infected
cells may have important implications for viral spread but
also in cardiovascular diseases such as atherosclerosis where
macrophages and smoothmuscle cells migrate into the atheroscle-
rotic plaques. Furthermore, both CCL5 and CX3CL1 promote
US28-dependent Ca2+ mobilization in a PTX-insensitive man-
ner in HCMV-infected smooth muscle cells, but not in U373
glioblastoma cells (Miller et al., 2012). Moreover, CCL5 further
enhances the US28-mediated invasiveness of glioma cells and
primary glioblastoma cultures (Soroceanu et al., 2011), show-
ing the relevance of ligand-induced signaling in US28-associated
pathologies.
In contrast to the agonistic effects of CX3CL1 on FAK, ERK,
and Ca2+ signaling, this chemokine can also act as an inverse
agonist as it decreases constitutive PLC and NFAT activation in
transiently transfected COS-7 and HEK293 cells (Casarosa et al.,
2001; McLean et al., 2004). However, CX3CL1 increases PLC acti-
vation in the absence of the C-terminus of US28 (Waldhoer et al.,
2003). It has been argued that the endocytosis of US28 camouﬂages
the agonistic properties of CX3CL1 and blocking endocytosis by
removing the C-terminus unmasks CX3CL1 agonism (Waldhoer
et al., 2003).
Since US28 has been linked to proliferative and cardiovascu-
lar diseases, inverse agonists targeting the constitutive activity
and chemokine binding to US28 might be attractive therapeu-
tic agents. The ﬁrst identiﬁed small molecule inhibitor of US28,
VUF2274, inhibits constitutive PLC activation, and CCL5 bind-
ing to US28 in transfected and HCMV-infected cells (Casarosa
et al., 2003b). Furthermore, VUF2274 also inhibits HIV entry
in US28-expressing cells. Later, analogs of VUF2274 and other
scaffolds were identiﬁed to inhibit CCL5 binding and constitu-
tive signaling of US28 (Hulshof et al., 2005, 2006; Vischer et al.,
2010; Kralj et al., 2013, 2014). Similar to CX3CL1,VUF2274 acts as
agonists on the C-terminal truncated mutant US28-300. Inter-
estingly, other small molecules retained their inhibitory properties
on US28-300 (Tschammer, 2014).
The DRY mutant US28-R3.50(129)A is unable to activate PLC
and several transcription factors (Maussang et al., 2006, 2009a;
Stropes and Miller, 2008; Slinger et al., 2010). However, US28-
R3.50(129)A-expressing cells are still able to form tumors in nude
mice, albeit at later time points as compared to WT-US28-
expressing cells (Maussang et al., 2006). This indicates that G
protein-independent signaling also contributes to the oncomod-
ulatory properties of US28.
UL33 also possesses a conserved DRY motif and promiscu-
ously couples to Gαi, Gαq, and Gαs proteins to constitutively
activate PLC, p38, and CREB in COS-7 cells (Casarosa et al.,
2003a). Although US27 and UL78 are required for viral dissemi-
nation (O’Connor and Shenk, 2011) and viral entry (O’Connor
and Shenk, 2012), these receptors have long been considered
‘silent’ as no signaling was detected. However, it was recently
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shown that US27 promotes cell proliferation, cell survival and
the expression of a limited number of genes (e.g., the pro-survival
factor Bcl-x and AP-1) when expressed in HEK293T, HeLa, and
COS-7 cells (Lares et al., 2013; Tu and Spencer, 2014). The DRY
mutant US27-R3.50(128)A decreased cell proliferation compara-
ble to rates observed in mock-transfected cells (Tu and Spencer,
2014). However, it remains to be investigated if US27 signals via G
proteins.
G protein-dependent signaling of Roseoloviruses-encoded GPCRs
HHV6-U12 and HHV7-U12 increase intracellular Ca2+ concen-
trations via a PTX-insensitive pathway in a ligand-dependent
manner in transfected erythroleukemia cells (Isegawa et al., 1998;
Nakano et al., 2003; Tadagaki et al., 2005). Furthermore, CCL19
and CCL21 (but not CCL17 and CCL22) induce HHV7-U12-
mediated chemotaxis of Jurkat cells (Tadagaki et al., 2005).
HHV6-U51 constitutively activates PLC and inhibits CRE in
COS-7 cells via Gαq, as was shown by the inhibiting effect
of the co-expressed Gαq/11 scavenger GRK2 (Fitzsimons et al.,
2006; Catusse et al., 2008; see “Desensitization and Intra-
cellular Receptor Trafﬁcking of Viral GPCRs”). Interestingly,
CCL2, CCL5, and CCL11 counteract constitutive HHV6-U51-
induced inhibition of CRE activity in a PTX-sensitive man-
ner, whereas only CCL5 increases constitutive PLC activation
and promotes Ca2+ mobilization in a PTX-insensitive man-
ner. These differential effects of the chemokines might be
explained by coupling of HHV6-U51 to distinct G protein sub-
types (Fitzsimons et al., 2006). The chemokines that bind to
HHV7-U51 induce Ca2+ mobilization most likely also via Gαq,
but do not promote chemotaxis of Jurkat cells (Tadagaki et al.,
2005).
MOLECULAR DETERMINANTS OF THE CONSTITUTIVE ACTIVITY OF
VIRAL GPCRs
According to the ternary complex model (De Lean et al., 1980),
an agonist is required to activate a GPCR. However, the dis-
covery of constitutively active GPCRs that show signaling in the
absence of agonists led to the extended ternary complex model
(Samama et al., 1993). In this revised model, a GPCR exists in
equilibrium between inactive and active conformations. Agonists
shift the equilibrium toward active receptors, whereas for consti-
tutively active GPCRs already a larger receptor fraction is in the
active conformation. Inverse agonists stabilize the inactive confor-
mation and consequently inhibit constitutive activity. This model
was latermodiﬁed to the cubic ternary complexmodel to incorpo-
rate the notion that G proteins can also bind to inactive receptors
(Weiss et al., 1996). More than 60 WT GPCRs are reported to
show constitutive activity that is inhibited by inverse agonists
(Seifert and Wenzel-Seifert, 2002). However, most of these recep-
tors are studied in recombinant cell lines using expression levels
that exceed physiological levels and the extent of constitutive activ-
ity varies with cellular background (Seifert and Wenzel-Seifert,
2002). On the other hand, constitutive activity of some GPCRs
has also been observed in native cells or tissues (Seifert and
Wenzel-Seifert, 2002). In addition, naturally occurring mutations
in some GPCRs increase constitutive activity and are associated
with human diseases (Smit et al., 2007; Tao, 2008).
Constitutive activity of ORF74
The constitutive activity of ORF74 is probably attributed to muta-
tions in residues that are highly conserved in otherGPCRs and that
may stabilize the inactive conformation. For example, the interac-
tion between R3.50, D/E3.49, and D/E6.30 is known as the ionic lock
(Ballesteros et al., 2001). Charge-neutralizingmutations inD/E3.49
orD/E6.30 increase the constitutive activity ofmanyhumanGPCRs
(Scheer et al., 1996; Kim et al., 1997; Ballesteros et al., 2001; Mon-
tanelli et al., 2004). Although the exact molecular basis for the
constitutive activity of ORF74 is not clear, D/E3.49, and D/E6.30
are substituted in ORF74 by V3.49(142) and R6.30(246), respectively,
which might possibly results in the disruption of the ionic lock.
Although the V3.49(142)D mutation did not decrease the consti-
tutive activity of ORF74 (Rosenkilde et al., 2000; Ho et al., 2001),
restoring the ionic lock by introducing an aspartic acid or glu-
tamic acid at R6.30(246) in ORF74 has to our best knowledge not
been investigated.
The highly conserved W6.48 in TM6 of GPCRs undergoes a
conformational change from pointing toward TM7 to pointing
toward TM5 upon receptor activation. This results in the move-
ment of the endof TM6away fromTM3and consequently disrupts
the ionic lock. This is known as the transmission switch and is
likely a common activation mechanism for most GPCRs (Trza-
skowski et al., 2012). In ORF74, W6.48 is mutated to C6.48(264),
which might inﬂuence the transmission switch. Another exam-
ple is N7.49 from the highly conserved NPxxY motif in GPCRs that
forms a network of hydrogen bondswithD2.50 (Urizar et al., 2005).
In ORF74 these residues are mutated to V7.49(310) and S2.50(93),
respectively, possibly resulting in the disruption of the water-
mediated hydrogen bonding network and stabilizing the active
conformation of TM7. Interestingly, the constitutive activity of
the S2.50(93)D and the V7.49(310)N mutants of ORF74 are unal-
tered compared to WT-ORF74 (Rosenkilde et al., 2000). However,
mutation of both residues in the S2.50(93)D/V7.49(310)N double
mutant might be required to stabilize the inactive conformation
of ORF74. Moreover, an H-bonding network between helix8 and
residues of TM2 and TM7 of ORF74 was proposed to stabilize the
end of TM7 (Verzijl et al., 2006). Disruption of helix8 by deletion
or point mutations [R7.61(322)W and Q7.62(323)P] distorts this net-
work and results in inactive mutants (Verzijl et al., 2006). Finally,
the L2.48(91)D and L2.51(94)D (but not N2.49(92)D and S2.50(93)D)
mutants of ORF74 are deﬁcient in constitutive activity but still sig-
nal in response to chemokines. In contrast toN2.49(92) andS2.50(93),
L2.48(91) and L2.51(94) are predicted to face the lipid bilayer. Possi-
bly, the substitution of hydrophobic residueswith charged residues
facing the cell membrane destabilizes the active conformation of
ORF74 (Rosenkilde et al., 2000). Transgenic mice carrying the
L2.48(91)D mutant of ORF74 fail to develop KS-like lesions (Holst
et al., 2001). This shows that the constitutive activity of ORF74
plays a key role in KS.
Constitutive activity of other vGPCRs
BILF1 (Paulsen et al., 2005), US28 (Casarosa et al., 2001), UL33
(Waldhoer et al., 2002), and HHV6-U51 (Fitzsimons et al., 2006)
are all constitutively active. As for ORF74, the molecular basis for
this constitutive activity is not well understood. For example, the
residues involved in the ionic lock, the transmission switch and
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the NPxxY motif are all conserved in US28. It has been proposed
that A3.35(114) might underlie the constitutive activity of US28 as
it would be too small to interact with residues from TM2, TM3,
and TM7 to stabilize the inactive conformation (Montaner et al.,
2013). However, no mutational studies on US28-A3.35(114) have
been performed to verify these predictions.
DESENSITIZATION AND INTRACELLULAR RECEPTOR TRAFFICKING OF
VIRAL GPCRs
After activation, the temporal and spatial signaling of GPCRs
is controlled by desensitization and internalization (Figure 6).
GPCR desensitization involves the phosphorylation of serine (S)
and threonine (T) residues in the C-terminus or sometimes the
ICLs of GPCRs (Nakamura et al., 1998; Kim et al., 2001; Liang
et al., 2002; Trester-Zedlitz et al., 2005; Watari et al., 2014) by
G protein-coupled receptor kinases (GRKs) and the subsequent
inhibition of G protein activation. GRKs are activated upon
docking to active GPCRs and thus regulate homologous desen-
sitization of GPCRs (Gurevich et al., 2012). The GRK family
is composed of 7 members (GRK1-7). Whereas GRK1, GRK7
(retina; Hisatomi et al., 1998) and GRK4 (testis; Premont et al.,
1996) display tissue-speciﬁc expression, GRK2, GRK3, GRK5,
and GRK6 are ubiquitously expressed throughout the body and
phosphorylate the majority of GPCRs. GRK2, and GRK3 contain
a N-terminal regulator of G protein signaling homology (RH)
domain which enables them to selectively interact with activated
Gαq (Ferguson, 2007) and allows GRK2 and GRK3 to inhibit Gαq-
mediated signaling of several GPCRs independently of receptor
phosphorylation (Carman et al., 1999; Sallese et al., 2000; Dhami
et al., 2004; Iwata et al., 2005; Giannotta et al., 2012). Second
messenger-dependent protein kinases such as PKA and PKC are
able to phosphorylate also inactive GPCRs and contribute to het-
erologous desensitization (Kelly et al., 2008). Other S/T kinases
involved in GPCR phosphorylation include Akt (Lee et al., 2001;
Doronin et al., 2002), casein kinase 1 (CK1; Tobin et al., 1997; Luo
et al., 2008) and CK2 (Hanyaloglu et al., 2001).
Phosphorylated GPCRs recruit β-arrestins to the plasma mem-
brane (Figure 6). The arrestin family is composed of four mem-
bers. Although arrestin1 and arrestin4 are speciﬁcally expressed
in the visual system to regulate rhodopsin, β-arrestin1 (also
known as arrestin2), and β-arrestin2 (arrestin3) bind to the
majority of non-visual GPCRs. β-arrestins sterically hinder the
coupling to G proteins and subsequently inhibit further activation
of G protein-mediated signaling. Upon binding to phosphory-
lated GPCRs, β-arrestins undergo conformational changes. This
results in the exposure of domains that interact with com-
ponents of the endocytic machinery such as clathrin and the
β2-adaptin subunit of the adaptor protein complex-2 (AP-2).
In this way, β-arrestins couple GPCRs to clathrin-coated pits
(CCPs) to facility receptor internalization (Figure 6). However,
β-arrestin-independent internalization has also been described
for some GPCRs [e.g., the protease-activated receptor 1 (PAR1;
Paing et al., 2002) and the leukotriene B4 receptor BLT1 (Chen
et al., 2004)] and might involve caveolae (lipid microdomains
in the plasma membrane containing caveolin proteins that act
as endocytic vehicles; Allen et al., 2007) or the direct interac-
tion of GPCRs with endocytic proteins (e.g., AP-2; van Koppen
and Jakobs, 2004). Desensitization and internalization are impor-
tant feedback mechanisms that protect cells from overstimulation
and malfunction of the desensitization machinery leads to var-
ious diseases. For example, almost all WHIM patients carry a
mutation in CXCR4 that results in a premature stop codon. This
causes the truncation of the C-terminus and results in impaired
desensitization and internalization of CXCR4, leading to aber-
rant CXCR4 signaling (Balabanian et al., 2005; Kawai and Malech,
2009).
Besides S/T residues, other determinants in the C-terminus
of GPCR can regulate internalization and trafﬁcking. For exam-
ple, AP-2 can directly bind to PAR1 by recognizing the YXXØ
motif (Y is tyrosine, X is any amino acid, Ø is an amino acid
with a bulky hydrophobic side chain). PAR1 internalizes inde-
pendently of β-arrestin, but depletion of AP-2 by siRNA indeed
inhibits constitutive internalization of this GPCR (Paing et al.,
2006; Chen et al., 2011). AP-2 is also reported to bind to the C-
terminus of the α1b-adrenergic receptor (α1b-AR) by recognizing a
poly-arginine motif. Deletion of this motif inhibits α1b-AR inter-
nalization (Diviani et al., 2003). Furthermore, AP-2 can recognize
di-leucine (LLor LI)motifs to induce the internalization of GPCRs
such as CXCR2 (Fan et al., 2001), CXCR4 (Orsini et al., 1999), and
β2AR (Gabilondo et al., 1997).
Internalized GPCRs trafﬁc to endosomes where they are
dephosphorylated by phosphatases (Figure 6). As a consequence,
they recycle back to the cell surface to participate again in signaling.
Alternatively, GPCRs can be sorted to lysosomes for degradation
(Magalhaes et al., 2012). Although determinants for GPCR sort-
ing are not completely understood, β-arrestins may regulate the
fate of internalized GPCRs. GPCRs that transiently interact with
β-arrestins recycle to the cell surface. In contrast, GPCRs that form
stable complexes with β-arrestin are degraded. Factors that con-
tribute to the stability of the GPCR/β-arrestin interaction include
the presence of phosphorylated S/T clusters in the C-terminus
of GPCRs (Oakley et al., 2001; Luttrell and Lefkowitz, 2002) and
ubiquitination of β-arrestin (Shenoy and Lefkowitz, 2003). Dif-
ferent recycling sequences have been identiﬁed in the C-terminus
of a considerable number of GPCRs that interact with recycling
sorting proteins such as Na+/H+ exchanger regulatory factor 1
(NHERF) and N-ethylmaleimide-sensitive factor (NSF; Magal-
haes et al., 2012). Alternatively, ubiquitination of GPCRs allows for
recognition by the endosomal-sorting complex required for trans-
port (ESCRT)machinery and targeting for degradation (Marchese
and Trejo, 2013). However, ubiquitin- and ESCRT-independent
mechanisms also contribute to target GPCR to lysosomes. The
family of GPCR-associated sorting proteins (GASP) and sorting
nexin-1 (SNX1) regulate the degradation of several GPCRs, but
the exact mechanism is unknown (Marchese et al., 2008). On the
other hand, GASP and SNX1 also bind to GPCRs that efﬁciently
recycle after internalization (Hanyaloglu and von Zastrow, 2008;
Marchese et al., 2008).
Importantly, β-arrestins not only arrest G protein-dependent
signaling, but can also initiate signaling by serving as ligand-
regulated scaffolds that recruit signaling proteins (Luttrell and
Gesty-Palmer, 2010; Figure 6). For example, several MAP kinases
(e.g., ERK1/2, JNK3, and p38) can be activated in a β-arrestin-
dependent manner (DeWire et al., 2007). β-arrestin-dependent
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FIGURE 6 | Desensitization and trafficking of GPCRs. Upon ligand binding,
GPCRs traditionally signal via G proteins (1). In addition, GPCRs are
phosphorylated on S andT residues in their C-terminus or ICLs by GRKs (2).
β-arrestins bind to phosphorylated GPCRs and prevent further coupling of G
proteins, a process known as desensitization (3). β-arrestins target
phosphorylated GPCRs for endocytosis via clathrin-coated pits (CCPs) by
scaffolding proteins of the internalization-machinery (4). Internalized
receptors may activate β-arrestin-dependent signaling (5). Internalized GPCRs
are subsequently sorted to recycling endosomes (6) or to lysosomes for
degradation (7).
FIGURE 7 | Sequences of the C-terminus of the different HHV-encoded
vGPCRs. Sequences start at the conserved NPxxY motif. The start of the
C-terminus of UL78 and BILF1, which lack the NPxxY motif, have been
determined by sequence alignment with the other vGPCRs. S/T residues are
underlined, Y residues are bold, and di-leucine motifs are italic. With the
exception of UL78, all HCMV-encoded vGPCRs contain a di-leucine motif in
their C-terminus. Although the C-terminus of the different vGPCRs differ in
length, all receptors contain serine (S)/threonine (T) residues in their
C-terminus. Only UL78 contains multiple S/T clusters (three or more S/T
residues in a row). Most vGPCRs contain at least oneY residue. For some
receptors, this Y residue is part of the NPxxY motif and unlikely to directly
interact with proteins such as AP-2 as the NPxxY motif is located in TM7.
signaling has been implicated in the cardiovascular system, the
immune system, and metabolic regulation, but also in patholog-
ical conditions such as cardiac failure and cancer (Luttrell and
Gesty-Palmer, 2010).
Desensitization and trafﬁcking of ORF74
Whereas several studies have focused on cellular signaling via G
proteins, details about signal termination and trafﬁcking of ORF74
remain largely unknown. Examination of the C-terminus of
ORF74 (Figure 7) reveals the presence ofmultiple S andT residues.
Overexpression of GRK4, GRK5, and GRK6 indeed desensitize
ORF74-induced PLC activation, cell proliferation, and foci for-
mation (Bais et al., 1998; Geras-Raaka et al., 1998a). Although
this suggests that S/T phosphorylation of ORF74 is involved in
desensitization, direct evidence of ORF74 phosphorylation and
subsequent β-arrestin recruitment is lacking. Surprisingly, over-
expression of GRK2 does not reduce PLC activation by ORF74
(Bais et al., 1998; Geras-Raaka et al., 1998a). In contrast to some
Frontiers in Pharmacology | Experimental Pharmacology and Drug Discovery March 2015 | Volume 6 | Article 40 | 12
de Munnik et al. vGPCRs modulate cellular signaling
human chemokine receptors [e.g., CXCR2, CXCR4, and CCR5
(Neel et al., 2005)], the C-terminus of ORF74 lacks a di-leucine
internalization motif. However, a classical tyrosine-based AP-2
binding motif (Y326GLF) is present in the C-terminus of ORF74.
Indeed, ORF74 constitutively interacts with components from
clathrin-coated vesicles, including AP-2, and siRNA-mediated
knockdown of these components lead to increased expression
of ORF74 at the cell membrane (Azzi et al., 2013). Further-
more, alanine-substitution of the Y residue within this AP-2
binding motif (ORF74-Y326A) inhibits the interaction with AP-2.
ORF74-Y326A accumulates at the cell surface and barely in intra-
cellular vesicles as compared to WT-ORF74 (Azzi et al., 2013).
This suggests that Y326 is essential for the constitutive inter-
nalization of ORF74, but does not exclude a putative role for
β-arrestin in ORF74 trafﬁcking. Interestingly, ORF74-Y326A fails
to downregulate Toll like receptor 4 (TLR4; Azzi and Gavard,
2014), which is a key player in the innate immune response
against KSHV (Lagos et al., 2008). This indicates that ORF74
regulates the cell surface expression of immune proteins by
constitutive internalization and provides a ﬁrst clue of the rel-
evance of ORF74 internalization. Whether TLR4 co-internalizes
with ORF74 within a protein complex or whether ORF74 affects
TLR4 expression via an autocrine/paracrinemechanism is hitherto
unknown. Although ORF74 was shown to interact with the lyso-
some sorting adaptorGASP (Heydorn et al., 2004), no information
is available about the fate of internalized ORF74. Furthermore,
β-arrestin-dependent signaling of ORF74 has hitherto not been
reported.
Desensitization and trafﬁcking of BILF1
To our best knowledge, internalization and endocytic trafﬁcking
of BILF1 has not been reported. However, a C-terminus dele-
tion mutant of BILF1 fails to downregulate MHC class I proteins
(see also “EBV”; Grifﬁn et al., 2013), indicating that the interac-
tion between BILF1 and MHC class I proteins might result in
co-internalization. The C-terminus of BILF1 contains several S
and T residues and a single Y residue (Figure 7) that might act as
β-arrestin and/or AP-2 binding sites, respectively.
Desensitization and trafﬁcking of HCMV-encoded GPCRs
The C-terminus of US28 contains several S/T residues (Figure 7)
and US28 is constitutively phosphorylated by GRK2, GRK5,
PKC, and CK2 (Mokros et al., 2002; Miller et al., 2003). Alanine-
substitutionof theseC-terminal S/T residues (US28-ST/A;Mokros
et al., 2002) or deleting the C-terminus (US28(1-314); Miller
et al., 2003; Waldhoer et al., 2003; Stropes et al., 2009) abro-
gated US28 phosphorylation and internalization, resulting in
increased cell surface expression and constitutive signaling as com-
pared to WT-US28 in heterologous expression systems (Miller
et al., 2003; Waldhoer et al., 2003) and in cells infected with
HCMV-US28(1-314; Stropes et al., 2009). US28, but not a
phosphorylation-deﬁcient mutant US28-S1-12A, induces translo-
cation of β-arrestin2-GFP to the plasma membrane. However,
β-arrestin2 resides in endocytic vesicles that are spatially distinct
from the US28-expressing vesicles (Droese et al., 2004). More-
over, US28 internalization is unaffected in embryonic ﬁbroblasts
from β-arrestin knockout mice (Fraile-Ramos et al., 2003) and
by a dominant-negative β-arrestin mutant (Droese et al., 2004).
This indicates that US28 internalizes independently of β-arrestins.
The C-terminus of US28 further contains a di-leucine motif and
a single tyrosine residue within an YHSM-sequence. US28 co-
localizes with AP-2 in intracellular vesicles (Droese et al., 2004)
and siRNA-mediated knockdown of AP-2 inhibited US28 inter-
nalization (Fraile-Ramos et al., 2003). Alanine-substitution of
the tyrosine residue in the C-terminus does not affect US28
internalization, but mutation of the di-leucine motif to ala-
nine reduces the rapid internalization of US28 (Droese et al.,
2004). However, a direct interaction between US28 and AP-2
has not been reported. US28 is primary located on early endo-
somes and recycling endosomes and recycles back to the plasma
membrane after internalization (Fraile-Ramos et al., 2001). How-
ever, US28 also colocalizes with markers of lysosomes (Tschische
et al., 2010) and interacts with SNX1 and GASP (Heydorn et al.,
2004). US28 does not colocalize with lysosome markers when co-
expressed with a dominant-negative mutant of GASP or siRNA
targeting GASP (Tschische et al., 2010). Surprisingly, overexpres-
sion of GASP increases US28-mediated PLC activation, whereas
shRNA-mediated knockdown of GASP or co-expression of a
dominant-negative GASP mutant inhibits US28-mediated PLC
activation (Tschische et al., 2010). These results indicate thatGASP
is involved in the regulation of US28 signaling. It is unknown
whether GASP targets US28 to a particular cellular compartment
to facilitate US28 signaling, whether GASP stabilizes a more active
conformation of US28 orwhetherGASP acts as a signaling partner
of US28.
Also UL33 (Fraile-Ramos et al., 2002), UL78 (Wagner et al.,
2012), and US27 (Fraile-Ramos et al., 2002; Niemann et al., 2014)
are primarily localized in endosomes of transfected or HCMV-
infected cells and show constitutive internalization (Fraile-Ramos
et al., 2002; Wagner et al., 2012). Different truncation mutants
show that the distal end of the C-terminus of US27 (at least the
last 14 residues) regulates its intracellular localization (Stapleton
et al., 2012). This region contains a single S residue and a di-
leucine motif (Figure 7), which might act as determinants for
US27 internalization.
Desensitization and trafﬁcking of Roseoloviruses-encoded GPCRs
HHV6-U51 internalizes in response to CCL2, CCL11, CCL19, and
XCL1, aswas shownby decreased cell surface expression of HHV6-
U51 in a stably transfected erythroleukemia cells as quantiﬁed by
ﬂow cytometry (Catusse et al., 2008). However, the mechanism
remains to be elucidated. Internalization and endocytic trafﬁcking
of the other three Roseoloviruses-encoded vGPCRs has hitherto
not been studied. The C-terminus of HHV6-U12, HHV6-U51,
HHV7-U12, and HHV7-U51 all contain multiple S and T residues
(Figure 7), which might act as putative β-arrestin binding sites. In
addition,HHV7-U12 contains a tyrosine residue in itsC-terminus,
which might facilitate AP-2 binding.
MODULATION OF HUMAN GPCRs BY VIRAL GPCRs
Cells usually express multiple GPCR subtypes that do not func-
tion in isolation but generate integrated responses by modulating
each other in dimers or via downstream crosstalk. GPCR het-
erodimerization can alter different aspects in the GPCR life cycle
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including ligand binding, signaling and trafﬁcking (Figure 8A).
For example, both positive and negative binding cooperativity has
been observed within GPCR heterodimers as a consequence of
intermolecular allosteric interactions. This explains why the lig-
and of one receptor is able to displace the ligand of a co-expressed
receptor. Negative binding cooperativity has been shown for the
chemokine receptors CCR2, CCR5, and CXCR4 (El-Asmar et al.,
2005; Sohy et al., 2007, 2009). Furthermore, GPCR heterodimer-
izationmay lead to potentiation or attenuation of signaling or even
changes in G protein selectivity. This was shown for the dopamine
D1 and D2 receptors that generate a novel PLC-mediated Ca2+
signal when co-expressed (Lee et al., 2004). The obligatory dimer-
ization between the GABAB1 and GABAB2 receptors forms one of
the best examples showing the functional relevance of dimeriza-
tionwith regard to proper cell surface delivery.When expressed on
their own, the two subunits are non-functional. GABAB1 is unable
to leave the ER after synthesis because this receptor contains an
ER retention motif within its C-terminus. The GABAB2 receptor
lacks this motif and trafﬁcs to the cell surface but is unable to bind
ligands. When co-expressed, the two receptors physically assemble
via a coiled-coil interaction of their C-terminuses and masking
the ER retention motif of GABAB1 (Margeta-Mitrovic et al., 2000;
Pagano et al., 2001). Heterodimerization might also promote co-
internalization of both receptors after stimulation of only one
protomer. Conversely, the internalization of one receptor can be
inhibited by forming heterodimers with a receptor that is resistant
to agonist-induced internalization (Terrillon and Bouvier, 2004).
On the other hand, GPCRs can modulate each other’s func-
tion without direct association. Two GPCRs might integrate their
signals downstream of receptor activation when they share signal-
ing molecules (Prezeau et al., 2010; Figure 8B). For example, the
inhibitory and activating signals of Gαi and Gαs-coupled recep-
tors converge at the level of AC, resulting in balanced cAMP
levels. Dimerization and downstream crosstalk are often difﬁcult
to distinguish (Vischer et al., 2011). Alternatively, GPCRs might
inﬂuence ligand binding or signaling of other GPCRs by scav-
enging shared signaling proteins or depleting signaling molecules
from a limited pool (Figure 8C). For example, as G protein and/or
β-arrestin coupling are required for high afﬁnity agonist binding
to some GPCRs, one GPCR might impair ligand binding of a sec-
ond GPCR by depleting the available G protein or β-arrestin pools
(Chabre et al., 2009). Finally, GPCRs might modulate ligand or
receptor expression levels by regulating transcription/translation
(Figure 8D). Viral and human GPCRs may modulate each other
to alter the functional properties of the latter in favor of the virus.
Modulation of human GPCRs by ORF74
Examples of modulating human GPCRs by ORF74 are rare and
fairly understudied. One study shows that the co-expression of
ORF74 inhibits Ca2+ mobilization induced by the thyrotropin-
releasing hormone receptor and the muscarinic acetylcholine M1
receptor in oocytes, HEK293 EM cells, and mouse pituitary AtT20
cells (Lupu-Meiri et al., 2001). This effect was further enhanced
by CXCL1 and inhibited by CXCL10. Depletion of intracellular
Ca2+ pools as a result of the constitutive signaling of ORF74 was
proposed as the underlying mechanism (Lupu-Meiri et al., 2001).
Modulation of human chemokine receptors by BILF1
BILF1 physically interacts with several chemokine receptors from
the CCR and CXCR family (Vischer et al., 2008) and the het-
eromeric complex between BILF1 and CXCR4 is composed of
at least four GPCRs (Nijmeijer et al., 2010). Although BILF1 does
not bind to CXCL12 (or other human chemokines, see Section
“Chemokine Binding to EBV-Encoded BILF1”), co-expression
of BILF1 inhibits CXCL12 binding to human CXCR4 and
consequently inhibits CXCR4 signaling (Nijmeijer et al., 2010).
Overexpression of Gαi restores CXCL12 binding and signaling
through CXCR4, indicating that the impaired CXCL12 binding
FIGURE 8 | G protein-coupled receptors can modulate each other’s
function via different mechanisms. (A) GPCRs can positively (+) or
negatively (–) modulate (dashed black arrows) ligand binding, signaling (solid
black arrow), or trafﬁcking via allosteric interactions (dashed white arrow)
within a heterodimer. (B) Crosstalk can be the result of signals (solid black
arrows) that integrate downstream of two GPCRs. (C) Scavenging of a limited
pool of shared signaling or scaffolding proteins (curved black arrow) might
modulate signaling or ligand binding (dashed black arrow) of co-expressed
GPCRs. (D) GPCRs can regulate the expression levels of other GPCRs, their
ligands or signaling proteins.
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to CXCR4 is the consequence of constitutive Gαi scavenging by
BILF1 rather than the transmission of conformational changes
across the BILF1/CXCR4 heteromeric complex (Nijmeijer et al.,
2010).
Modulation of human GPCRs by HCMV-encoded GPCRs
The human chemokine receptor CCR1 binds with high afﬁnity
to CCL5, but only induces a small PTX-sensitive activation of
NF-κB. However, when US28 is co-expressed, CCL5 induces a
robust PTX-sensitive increase in NF-κB activation (Bakker et al.,
2004), which is mediated by CCR1 as co-expression of chemokine
binding-deﬁcient mutant N-US28 (Casarosa et al., 2003b) also
enables NF-κB signaling in response to CCL5 (Bakker et al., 2004).
On the other hand,US28-R3.50(129)A fails to unmask CCR1 signal-
ing, showing that the crosstalk between US28 and CCR1 requires
the constitutive activity of US28 (Bakker et al., 2004). Likewise,
US28 and N-US28 (but not US28-R3.50(129)A) potentiates LPA-
mediated Ca2+ mobilization in HCMV-infected smooth muscle
cells (Miller et al., 2012).
Interestingly, while US27 and UL78 are described as silent
orphan receptors, they are able to modify signaling of CXCR4.
US27 increases CXCR4 expression in HEK293T cells and potenti-
ates Ca2+ mobilization and chemotaxis in response to CXCL12
(Arnolds et al., 2013), whereas UL78 inhibits these CXCR4-
mediated responses in monocytes (Tadagaki et al., 2012). These
opposite effects might reﬂect the need of the virus to escape
immune surveillance or promote viral spread by cell migration
during different stages of HCMV infection.
UL33 and UL78 form heterodimers with human CCR5 and
the functional consequences of these interactions depend on the
dimerization partner and functional read-out (Tadagaki et al.,
2012). BothUL33 andUL78 impair CCL5-induced internalization
of CCR5. However, while UL33 almost completely blocks CCR5-
induced PLC activation and Ca2+ mobilization, UL78 increases
these responses. On the other hand, both viral GPCRs had a
negative effect on CCR5-mediated cell migration (Tadagaki et al.,
2012).
Modulation of human GPCRs by Roseoloviruses-encoded GPCRs
Comparable to the crosstalk betweenUS28 andCCR1,HHV7-U12
and U51 unmask CCL19 and CCL22-induced Ca2+ mobilization
mediated by CCR4 and CCR7 in murine L1.2 cells (Tadagaki et al.,
2007). In the absence of U12 and U51, CCR4 only responds
to CCL22 and CCR7 only to CCL19 (Figure 4). Furthermore,
although CCL19 and CCL22 induce U12- and U51-mediated
Ca2+ mobilization in human erythroleukemia K562 cells (Tada-
gaki et al., 2005), these vGPCRs are unable to promote Ca2+
mobilization in response to CCL19 or CCL22 in murine L1.2 cells
(Tadagaki et al., 2007). Surprisingly, these unmasked signals are
not observed in cell migration assays (Tadagaki et al., 2007).
MODULATION OF HUMAN RTKs BY VIRAL GPCRs
In addition to GPCRs that modulate each other’s functioning,
also GPCRs and RTKs are organized within communication net-
works. RTKs comprise a class of transmembrane proteins that
are structurally and functionally distinct from GPCRs. RTKs are
commonly activated by growth factors that induce formation of
receptor dimers, resulting in the autophosphorylation of intra-
cellular tyrosine residues and the subsequent binding of adaptor
proteins that activate downstream signaling pathways such asMAP
kinases (Lemmon and Schlessinger, 2010). The term ‘transactiva-
tion’ is often used to describe RTK activation by a GPCR ligand
without the addition of growth factors or vice versa (Daub et al.,
1996). GPCRs and RTKs can transactivate each other via differ-
ent mechanisms, with GPCRs acting either upstream (Figure 9)
or downstream (Figure 10) of RTKs. RTK transactivation can
be ligand-dependent resulting in both autocrine and/or paracrine
signaling (Figures 9A,B) or ligand-independent (Figures 9C,D;
Delcourt et al., 2007a). Only ligand-dependent mechanisms can
lead to the transactivation of RTKs on neighboring cells that
do not co-express the GPCR. One of the best characterized
ligand-dependent mechanisms for RTK transactivation involves
the GPCR-induced activation of a membrane-anchored metal-
loproteinase, resulting in the release of an membrane-anchored
growth factor-precursor which subsequently activates its cognate
receptor (Figure 9A; Wetzker and Bohmer, 2003). This mech-
anism has only been described for the transactivation of the
epidermal growth factor receptor (EGFR) and in a single case
for the insulin-like growth factor 1 receptor (IGF-1R; Oligny-
Longpre et al., 2012). Alternatively, transactivation of RTKs might
also involve GPCR-induced de novo synthesis of growth factors
(Figure 9B). RTK transactivation by ligand-independent mech-
anisms involves the phosphorylation of the RTK by a tyrosine
kinase acting downstream of GPCR signaling (Figure 9C), GPCR-
induced inactivation of tyrosine phosphatases that control RTK
activity (Figure 9C; Wetzker and Bohmer, 2003) or the formation
of a GPCR/RTK-signaling complex (Figure 9D; Delcourt et al.,
2007a). Transactivation of RTKs often accounts for the prolifera-
tion, differentiation, migration, and survival responses promoted
by GPCRs. For example, transactivation of IGF-1R by GABAB
receptor protects neurons from apoptosis (Tu et al., 2010). An
antibody that prevents IGF-1 binding to IGF-1R could not antag-
onize this transactivation. Instead, the Gαi/o-inhibitor PTX, a
PLC inhibitor, a Ca2+ chelator, and siRNA-mediated knockdown
of FAK1 all impair IGF-1R transactivation by GABAB and show
the requirement of these downstream proteins and second mes-
senger. Furthermore, IGF-1R was co-immunoprecipitated with
GABAB1, but there is no evidence that an interaction between
the two receptors is essential for the observed crosstalk (Tu et al.,
2010).
Reciprocally, examples of RTKs that transactivate GPCRs are
less abundant and involve the de novo synthesis (Figure 10A) or
the enzymatic activation (Figure 10B) of GPCR ligands that act
in an autocrine/paracrine manner, or a physical interaction with
GPCRs (Figure 10C). For instance, activation of IGF-1R results in
the upregulation of CCL5 on the transcriptional level and the sub-
sequent activation of CCR5-mediated chemotaxis (Figure 10A;
Mira et al., 2001). Furthermore, transactivation of the sphinogo-
sine 1 phosphate receptor S1P1 is regulated by the formation of
its ligand S1P from a precursor via IGF-1R-, TrkA-, or plateled-
derived growth factor receptor (PDGFR)-mediated activation of
sphingosine kinase (SphK;Figure 10B; Hobson et al., 2001; Toman
et al., 2004; El-Shewy et al., 2006). Ligand-independent mech-
anisms also exist for transactivation of GPCRs and involve the
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FIGURE 9 | Different mechanisms of receptor tyrosine kinase (RTK)
transactivation. (A) GPCR-induced activation of a membrane-anchored
metalloproteinase results in the release of a growth factor which activates
its cognate RTK in a autocrine and/or paracrine manner. (B) GPCRs
regulate the expression and secretion of growth factors that transactivate
RTKs in a autocrine and/or paracrine manner. (C) Ligand-independent
transactivation of RTKs via the GPCR-induced activation (black arrow) or
inhibition of tyrosine kinases or phosphatases, respectively. (D) GPCRs
transactivate RTKs within a protein complex, possibly via allosteric
interactions (dashed white arrow).
FIGURE 10 | Different mechanisms of GPCR transactivation. (A)
RTK-induced de novo synthesis of GPCR ligands that activate their cognate
receptor in an autocrine and/or paracrine manner. (B) RTK-induced enzymatic
activation and secretion of GPCR ligands that activate their cognate receptor
in an autocrine and/or paracrine manner. (C) RTKs might transactivate
interacting GPCRs from internalized vesicles, leading to extracellular
-signal-regulated kinases (ERK) activation. The exact mechanism and
requirement of the RTK/GPCR interaction for transactivation is not clear.
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formation of constitutive complexes between CXCR4 and IGF-1R
(Akekawatchai et al., 2005), pituitary AC activating polypeptide
type 1 receptor (PAC1R) and IGF-1R (Delcourt et al., 2007b)
and between S1P1 and PDGFR (Alderton et al., 2001). How-
ever, the nature and the role of these interactions for GPCR
transactivation are not well understood but might involve the sig-
naling from intracellular vesicles of co-internalized GPCR/RTK
complexes (Figure 10C; Waters et al., 2003).
Modulation of human RTKs by ORF74
Studies examining themodulation of humanRTKs byORF74 have
hitherto been limited to the angiogenic VEGF receptors VEGFR-1
and VEGFR-2 and the mechanism depicted in Figure 9B. VEGF
plays an important role in the angiogenesis of KS and a small
molecule inhibitor of the VEGFR-1 has a positive outcome in the
majority of AIDS-related KS patients in a phase I study (Arasteh
and Hannah, 2000). ORF74-expressing endothelial cells increase
VEGF secretion (Bais et al., 1998) via p38- and MAP kinase-
mediated activation of HIF-1α (Sodhi et al., 2000), leading to
VEGFR-2 activation and the subsequent survival (Bais et al., 2003),
growth, andmicrotubule formation of endothelial cells (Bais et al.,
1998). These effects could be inhibited by VEGF (Bais et al., 1998)
orVEGFR-2 blocking antibodies (Bais et al., 2003). Indeed, in vivo
models show that transgenic expression of ORF74 in mice results
in VEGF secretion and the development of highly vascularized
lesions (Yang et al., 2000).
Besides the angiogenic role of VEGF/VEGFR in KS, IGF-1R
(Catrina et al., 2005), and PDGFR (Rossi et al., 2009) also play a
role in KS. Furthermore, studying the KSHV secretome reveals
secretion of several growth factors, including IGF-1, PDGF and
EGF (Schwarz and Murphy, 2001; Jensen et al., 2005; Sharma-
Walia et al., 2010). However,whetherORF74 transactivates human
RTKs other than the VEGF receptors remains to be elucidated.
Modulation of human RTKs by other vGPCRs
Co-transfection of US28 and the membrane-anchored precur-
sor Heparin-binding EGF-like growth factor (HB-EGF) results
in increased levels of soluble EGF in the supernatant of intesti-
nal epithelial Caco-2 cells as compared to US28-deﬁcient Caco-2
cells, suggesting that US28 cleaves HB-EGF (Bongers et al., 2012).
Furthermore, transgenic co-expression of US28 and HB-EGF in
the intestines of mice results in an increased incidence and faster
development of polyps as compared to mice only expressing HB-
EGF (Bongers et al., 2012). These results indicate that US28 might
transactivate EGFR.
Moreover, US28 constitutively promotes VEGF secretion
(Maussang et al., 2006) via COX-2 (Maussang et al., 2009b) and
STAT3 (Slinger et al., 2010) in transfected NIH-3T3 cells and
HCMV-infected glioblastoma cells (Maussang et al., 2006; Soro-
ceanu et al., 2011). Furthermore, in vivo studies show that US28
increases the VEGF plasma levels in a xenograft mouse model
that developed highly vascularized tumors (Maussang et al., 2006),
indicating that US28 contributes to an angiogenic phenotype in
proliferative diseases.
Constitutive BILF1 signaling also results in VEGF secretion
(Lyngaa et al., 2010), but knowledge about a mechanism and any
downstream effects is lacking.
Besides a role in transactivation, EGFR (Wang et al., 2003),
and PDGFR (Soroceanu et al., 2008) have been proposed to act
as co-receptors for HCMV entry. HCMV directly interacts with
EGFRorPDGFRvia its envelop glycoprotein gB.Antibodies block-
ing EGFR or PDGFR, or siRNA-mediated knockdown of PDGFR
inhibit HCMV gene expression and viral replication. EGFR- or
PDGFR-negative cells are not permissive to HCMV infection, but
expression of EGFR or PDGFR renders these cells susceptible to
HCMV.However, others were unable to reproduce the results with
the PDGFRblocking antibodies and silencingPDGFRwith shRNA
did not inhibit HCMV entry. However, overexpression of PDGFR
enhanced HCMV entry (Vanarsdall et al., 2012). It was proposed
that PDGFR does not interact directly with HCMV but enhances
HCMV entry via a non-canonical pathway involving dynamin-
dependent endocytosis (Vanarsdall et al., 2012). Likewise, the role
of EGFR as a HCMV co-receptor has been challenged by contra-
dicting results showing that an EGFR blocking antibody or small
molecule inhibitor did not decrease HCMV entry in ﬁbroblast,
epithelial or endothelial cell (Isaacson et al., 2007). These contra-
dicting results might be due to cell type-dependent mechanisms
underlying HMCV entry and other receptors might substitute for
EGFR/PDGFR. This could explain why EGFR is not expressed on
all HCMV-permissive cell types, such as monocytes/macrophages,
dendritic cells, and neutrophils (Isaacson et al., 2007).
CONCLUDING REMARKS AND FUTURE PERSPECTIVES
Human herpesviruses have successfully developed multiple strate-
gies to escape immune surveillance and promote viral dissemina-
tion, which resulted in a high infection rate among the human
population. Herpesviruses are usually harmless for most people,
but can cause severe pathology in immunocompromised patients.
All herpesviruses from the β and γ subfamily encode at least
one vGPCR that shows homology to human chemokine recep-
tors. These vGPCRs have been modiﬁed to obtain unique features,
including constitutive activity and binding of a broad range of
chemokines, and are used by the virus to take over the control
of the host cell for its own beneﬁt. In this review, we described
six different ways by which vGPCRs (potentially) modulate cellu-
lar signaling (Figure 11). Constitutive and chemokine-induced G
protein signaling have exhaustively been studied for most vGPCRs
using in vitro heterologous expression andHCMV-infectionmod-
els, as well as xenograft and transgenic in vivo models. Although
vGPCRs have been detected in (patho)physiological patient sam-
ples (e.g., HCMV-positive glioblastoma tumors or KS lesions),
little is yet known on their in situ (constitutive) signaling activi-
ties. Constitutive signaling is proportional to receptor expression
levels, hence quantiﬁcation of receptor levels in patient samples
might allow some comparison with experimental models. Fur-
thermore, cellular signaling pathways activated by vGPCRs might
be cell type-dependent. For example, BILF1 activates NF-kB in
COS-7 cells but not in Burkitt’s lymphoma cells or lymphoblas-
toid B cells (Beisser et al., 2005), showing the importance of
using (patho)-physiologically relevant cell systems.Whereasmany
signaling properties of vGPCRs have been studied in recombi-
nant systems using conventional cell lines (i.e., COS-7 cells),
also disease-relevant cell lines such as glioblastoma cell lines
for US28 and primary B cells from KS patients for ORF74 are
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FIGURE 11 |Viral G protein-coupled receptors can modulate cellular
signaling by means of different mechanisms. vGPCR are expressed at
the cell surface of HHV-infected cells. For most vGPCRs, canonical
mechanisms of host cell modulation has been studied in detail and shows
that vGPCRs can signal through G proteins (1) in a constitutively active
manner (2). Chemokine binding might modulate constitutive signaling (3).
Less knowledge is available on non-canonical mechanisms that involve the
interaction of vGPCRs with proteins from the endocytic machinery (e.g.,
β-arrestin) (4). In addition, vGPCR may modulate the function of human
GPCRs (5) or RTKs (6).
used. Furthermore, HCMV-infected cells are often used to study
US28 signaling in the viral context. HCMV-mutants such as
US28-R3.50(129)A and N-US28 have been developed to study G
protein-coupling and chemokine binding in HCMV-infected cells
instead of recombinant systems (Stropes and Miller, 2008). Such
tools are useful to study the signaling of the other vGPCRs in a
viral setting.
In this reviewwe further discussed how vGPCRs exploit human
proteins from the endocytic machinery or modulate the signaling
of humanGPCRs or RTKs (Figure 11). These subjects havemainly
been neglected and are fairly understudied for most vGPCRs.
Although endocytosis of US28 was the subject of several stud-
ies, still many questions remain unanswered. For example, S/T
residues in the C-tail of US28 seem to be important for endo-
cytosis (Mokros et al., 2002), yet the exact role of β-arrestin is
still uncertain (Fraile-Ramos et al., 2003; Droese et al., 2004). Fur-
thermore, the endocytic trafﬁcking of most other vGPCRs have
hitherto escaped attention. Are constitutively active vGPCRs inter-
nalized in the absence or presence of chemokines and if so, how
is endocytic trafﬁcking regulated? Does endocytosis contribute to
viral dissemination by co-internalization of proteins key for anti-
viral immune responses? Do US28 and BILF1, which possibly
also contribute to tumor formation via G protein-independent
signaling (see “G Protein-Dependent BILF1 Signaling” and “G
Protein-Dependent Signaling of HCMV-Encoded GPCRs”) signal
via β-arrestin-dependent mechanisms from intracellular com-
partments? Do apparent silent vGPCRs (e.g., UL78) signal via
G protein-independent mechanisms and/or modulate GPCRs
(chemokine receptors in particular) or RTKs through dimer-
ization and/or transactivation? These subjects warrant further
investigation to gain insight in the different properties of vGPCRs.
Since vGPCRs are identiﬁed to modify cellular signaling and
are associated with HHV-associated pathologies, they might serve
as potential drug targets. Speciﬁc inhibitors targeting vGPCR
functioning might be used as research tools or for clinical antivi-
ral intervention. Small non-peptidergic compounds that inhibit
constitutive activity and chemokine binding have hitherto only
been developed for US28. However, these US28 compounds dis-
play a low μM potency despite signiﬁcant optimization efforts
(Hulshof et al., 2005, 2006; Vischer et al., 2010; Kralj et al., 2011,
2013, 2014). Nanobodies are the antigen-binding fragments of a
unique class of heavy chain-only antibodies found in camelids
and are gaining popularity as targets for GPCRs due to their rel-
ative small size, high afﬁnity, and speciﬁcity (Mujic-Delic et al.,
2014). Nanobodies targeting CXCR4 and CXCR7 have recently
been developed and induce CXCR4-mediated stem cell mobiliza-
tion in cynomolgusmonkeys, inhibit CXCR4-mediatedHIV entry
(Jahnichen et al., 2010) and inhibit CXCR7-mediated head and
neck cancer tumor growth in a xenograft mouse model (Maus-
sang et al., 2013), respectively. The nanobody-based targeting of
vGPCRs might be an attractive and promising strategy for the
development of research tools, diagnostics, and/or therapeutics.
Taken together, tools targeting viral GPCRs and knowledge on
the mechanisms by which vGPCRs modulate cellular signaling
will provide insight into viral spread and herpesvirus-associated
pathologies.
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